Overview

Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia

Status:
Active, not recruiting

Trial end date:
2021-04-30

Target enrollment:

Participant gender:

Summary

To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia

Phase:

Phase 2

Details

Lead Sponsor:

Angion Biomedica Corp

Collaborator:

CTI Clinical Trial and Consulting Services

Treatments:

Mitogens